In the latest cohort study conducted by Dr.Camille Roubille and colleagues explored 7-year tolerability profile of glucocorticoids (GC) for early rheumatoid arthritis (RA and found that -Low-dose glucocorticoids appear to be safe over the long term for early active rheumatoid arthritis (RA), French researchers. The only caveat is that they should be used with disease-modifying antirheumatic drugs (DMARDs), and for the shortest duration at the lowest possible amounts. The study has been published in Annals of the Rheumatic Diseases.
The researchers examined data for 602 patients with RA from the early arthritis Etude et Suivi des POlyarthrites Indifférenciées Récentes (ESPOIR) cohort (<6 months disease duration) stratified into two groups: with or without GC treatment at least once during follow-up (median 7 years (IQR 0.038–7.65)). The main outcome was a composite of death, cardiovascular disease (including myocardial ischaemia, cerebrovascular accident and heart failure), severe infection and fracture.
Of the total 602 patients with RA enrolled in study , (476 women (79%), mean age 48±12 years), 386 with GC (64.1%) received low-dose prednisone (mean 3.1±2.9 mg/day for the entire follow-up): 263 started GC during the first 6 months (68%), and the mean duration of total GC treatment was 1057±876 days. As compared with patients without GC (216 (35.9%)), those with GC showed greater use of non-steroidal anti-inflammatory drugs, synthetic and biological disease-modifying antirheumatic drugs and had more active disease disability, higher C reactive protein and anticitrullinated protein antibody levels. Among 65 events (7 deaths, 14 cardiovascular diseases, 19 severe infections and 25 fractures), 44 and 21 occurred in patients with and without GC (p=0.520). Infections were more frequent, although not significantly, in patients with than without GC (p=0.09). On weighted Cox proportional-hazards analysis, with use of propensity score and inverse-probability-of-treatment weighting, and including age, gender, history of hypertension and GC treatment, outcomes did not differ with and without GC (p=0.520; HR=0.889; 95% CI 0.620 to 1.273).The results support the good safety profile of low-dose glucocorticoid therapy for early RA.
The authors concluded that this 7-year analysis of the ESPOIR cohort supports the good safety profile of very low-dose GC for early active RA. “Although our findings need further confirmation, they strongly support the current recommendations that glucocorticoids should be used for early RA, with DMARDs, for the shortest period and at the lowest possible dose.”
For more details click on the link: http://ard.bmj.com/content/early/2017/02/17/annrheumdis-2016-210135
Dr. Kamal Kant Kohli
Latest posts by Dr. Kamal Kant Kohli (see all)
- Once a month injectable available for schizophrenia - November 20, 2018
- Lithotripsy improves erectile function in impotence - November 18, 2018
- Rifamycin approved for travellers’ diarrhoea by FDA - November 17, 2018